INSM (44) ROIV (44) ALNY (55) VTRS (57) ⌘ Pro Terminal →

United Therapeutics Corporation (UTHR) — RQD Stock Rating Cockpit

$598.72 +0.87% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $601.09

United Therapeutics Corporation (UTHR) earns a Roarable Rating of A- (Buy) with 82/100 RQD Confidence. High-quality cash engine (88% profit margin, 20% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 82/100 (A-) historically ranked in the Top 7% of excess returns over the next 90 days (+8.6% avg 90D alpha vs SPY • 71.9% hit rate) →

ROARABLE A- • BUY Cap $25.46B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on UTHR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is UTHR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, United Therapeutics Corporation (NASDAQ: UTHR) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 82/100 at a spot price of $598.72 (+0.87% 1D, market cap $25.46B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, UTHR ranks #10 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does UTHR compare to INSM and ROIV in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), UTHR carries a Roarable A- (82/100 RQD), trailing P/E of 19.1x, gross margin of 87.9%, and ROIC of 20.1%. By comparison, INSM (Insmed Incorporated) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $24.37B) and ROIV (Roivant Sciences Ltd.) posts a D grade (44/100 RQD, P/E N/A, ROIC -14.0%, cap $27.10B). Among the 5-stock peer group, UTHR leads on earnings multiple (19.1x) while ALNY leads on capital efficiency (21.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for UTHR?

▼

Per UTHR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001082554), United Therapeutics Corporation generated $3.18B in revenue (+10.6% YoY), $1.33B in net income, and $1.04B in free cash flow against $7.88B in total assets and $352.7M in total debt. Key quantitative strengths: Strong cash generator (88% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $601.11 (+0.40%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 32.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 82/100 (A-) historically ranked in the Top 7% of excess returns over the next 90 days (+8.6% avg 90D alpha vs SPY • 71.9% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • A-

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk A-

Each axis scored 0–20

12M PRICE TARGET CONE+10.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for UTHR)Realized 20D OHLCV Swing Band: ±6.1%

Deterministic 5-Pillar Attribution (82/100 Composite)

🔍 WHY UTHR SCORES 82/100 (A-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (22% of score)

Altman Z-Score 22.52 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (21% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▼ #1 Drag / Risk Factor: Cash Engine Quality15/20 pts (-5 pt drag)

Capital intensity & 46.9% operating margin leave 5 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B+$543.40+1.9% Next Q

Q2 (-2Q)

Grade B+$553.88+6.7% Next Q

Q3 (-1Q)

Grade A-$591.20+1.3% Next Q

Current

Grade A-$598.72+8.6% Hist 90D α

Trajectory: B+ (74) → A- (82)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the UTHR Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 82/100 (A-) score, UTHR faces multiple-compression risk if 19.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 85.4% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($530.33) or 200D SMA ($532.79) invalidates the momentum regime and cuts Target Base ($663.38) toward Bear Floor ($490.95).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $UTHR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “UTHR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 82%NO 18%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

66.930 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

22.52>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

9 / 99-Pt Accounting

52-WEEK LASER RANGE94% OF RANGE

L: $430$598.72H: $610

1. Money & Cash Health● HEALTHY

Are profits real cash in the bank?

Real cash coming in backs up reported profits (88% profit margin and healthy balance-sheet cushion).

Factor Grade: BRQD 15 / 20

2. Big Money & Insiders● BUYING

Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: A-RQD 33 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: A-RQD 34 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bullish on UTHR

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (75)

20.1% ROIC with 87.9% gross margin and 4.09% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (90)

Altman-Z 22.52 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BULLISH (82)

33/40 institutional & smart-money positioning score with 16/20 macro alignment.

Bull Case: Why Buyers Like UTHR

✓Strong cash generator (88% profit margin)—profits are backed by real money, not accounting tricks.
✓Big institutional funds and options desks are actively positioning on the bullish side.
✓Company leadership has skin in the game with net positive insider conviction.

Bear Case: What Could Go Wrong

!Broader market pullbacks can still drag down strong stocks in the short run.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (UTHR Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

UTHR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +3.01%📐 HORIZONTAL RANGE

2026-11-02O $586.5H $598.7L $586.5C $598.7VOL 370.6K

RES: $612.3SUP: $451.5SMA50: $530.3SMA200: $532.8

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

UTHR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 UTHR Butterfly Map → + Track UTHR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

12.5%/yr Implied 5Y Growth

vs. +10.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on UTHR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for UTHR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for UTHR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (UTHR)

Health Care Rank #10 of 1016 ⚔️ INSM vs UTHR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (UTHR vs. INSM, ROIV, ALNY, VTRS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, United Therapeutics Corporation (UTHR) ranks #10 by composite RQD confidence (82/100, grade A-) and #63 by equity capitalization ($25.46B). Within this direct 5-issuer industry benchmark cohort, UTHR leads on earnings valuation at 19.1x trailing P/E, while ALNY leads on capital efficiency and profitability with 21.3% ROIC and 81.8% gross margin. UTHR currently leads its immediate peer cohort in composite quantitative strength at 82/100 (A-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
UTHR ACTIVE United Therapeutics Corporation	A-	82/100	19.1x	87.9%	20.1%	+0.87%	$25.46B	Benchmark Subject
INSM Insmed Incorporated	D	44/100	—	79.7%	-35.0%	+0.89%	$24.37B	/insm-vs-uthr →
ROIV Roivant Sciences Ltd.	D	44/100	—	—	-14.0%	-1.63%	$27.10B	/roiv-vs-uthr →
ALNY Alnylam Pharmaceuticals Inc.	D+	55/100	74.2x	81.8%	21.3%	-5.17%	$23.28B	/alny-vs-uthr →
VTRS Viatris Inc.	D+	57/100	—	35.2%	-8.1%	-0.86%	$22.05B	/vtrs-vs-uthr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001082554

In its most recent audited fiscal period (FY2025, filed 2025-12-31), United Therapeutics Corporation (UTHR) reported GAAP revenue of $3.18B (+10.6% vs. FY2024 revenue of $2.88B , and +36.7% cumulative change since FY2023) , GAAP net income of $1.33B, operating cash flow of $1.56B, and free cash flow of $1.04B (-3.7% YoY). On the balance sheet, UTHR closed FY2025 with $7.88B in total assets against $352.7M in total debt (Altman Z-Score: 22.52, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.18B	$1.33B	$1.56B	$1.04B	$7.88B	$352.7M
FY2024 (FY)	2024-12-31	$2.88B	$1.20B	$1.33B	$1.08B	$7.36B	$414.0M
FY2023 (FY)	2023-12-31	$2.33B	$984.8M	$978.0M	$873.3M	$14.00B	$3.28B

3. UTHR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is UTHR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does UTHR compare to INSM and ROIV in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for UTHR?

Where is UTHR trading relative to its 50-day, 200-day, and 52-week technical levels?

UTHR last traded at $598.72 (+0.87% on volume of 518,613 shares), positioning the stock +12.90% above its 50-day simple moving average ($530.33) and +12.37% above its 200-day simple moving average ($532.79). Across its 52-week range of $430.02 to $609.99, UTHR sits at the 93.7% percentile with a 14-day RSI of 66.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.1% ($562.20 to $635.24).

UTHR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell UTHR stock right now?

United Therapeutics Corporation (UTHR) currently earns a Roarable Rating of A- (Buy — BUY) with 82/100 RQD Confidence. High-quality cash engine (88% profit margin, 20% return on capital) with steady institutional support.

What is UTHR's 12-month price target and RQD AI Jury consensus?

UTHR's 12-month base price target is $663.38 (range $490.95 to $782.79), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: UTHR RQD Cockpit UTHR 12M Forecast UTHR Earnings & Move UTHR Dividends & DRIP UTHR Insiders & 13F UTHR Whale Options UTHR Profit Sankey UTHR News & Why

ROARABLE RATING BRIEF • RQD 82/100 (A-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

UTHR — United Therapeutics Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:12:51Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, UTHR scores 82 out of 100, grade A-, labeled "Roarable Buy — Superior Risk/Reward." The five pillars are: Fundamental Cash Engine 15/20 (ROIC 20.1%; FCF yield 4.09%), Whale 13F Flow 16/20 (institutional accumulation and options positioning), Insider Conviction 17/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 16/20 (Beta 0.95; sector sensitivity), and Forensic Balance Sheet 18/20 (Altman Z 22.52; Piotroski F 9/9; Debt/Equity 0.05).

For a prospective investor, the strongest pillar is the forensic balance sheet, which indicates low leverage and high reported financial-health scores. The cash-engine pillar is comparatively weaker: a 4.09% FCF yield is a valuation tradeoff, meaning the stock is priced at a level where cash generation supports a moderate rather than high yield. Insider and institutional flow pillars point to concentrated positive positioning signals, but these are short-horizon indicators and do not guarantee future returns. The macro pillar's beta of 0.95 suggests price movement roughly in line with the broader market. Upside drivers implied by the data include sustained margin strength and insider/institutional activity; valuation tradeoffs include a 19.1x trailing P/E against a 17.8x forward P/E. This section is analytical and educational, not personalized advice.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
$593.54	$25.46B	19.1	17.8	12.5	31.12	0%	0.95	$430.02 - $609.99	20.1%

Business

United Therapeutics Corporation is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the Profile section. Per the Profile section, the company has a market capitalization of $25.5B. The source data does not describe specific products, customers, or revenue-generation model beyond the sector and industry classification. Gross margin of 87.9% and operating margin of 46.9% are reported in the market data section.

Open Questions

What are the company's specific products and revenue sources behind the reported figures?
What were reported EPS values for FY 2023–FY 2025, which are listed as N/A?
What was the FY 2023 cash balance, and why does FY 2023 debt ($3276.4M) differ so sharply from later periods?
What is the supply-chain dependency profile, since the Butterfly graph reports no links?
Does the Liquidia (LQDA) move relate directly to UTHR, or is it sector-adjacent only?

UTHR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for United Therapeutics Corporation (UTHR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to UTHR Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 7h ago

United Therapeutics (UTHR): Can the Profit-Machine Biotech Finally Crack the S&P 500?

Yahoo Finance report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 10h ago

Family trusts sell 9,500 United Therapeutics (UTHR) shares under a pre-arranged trading plan.

Stock Titan report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Benzinga • 13h ago

Liquidia Shares Surge 42.48% After Hours - United Therapeutics (NASDAQ:UTHR), Liquidia (NASDAQ:LQDA)

Benzinga report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 16h ago

CEO trusts sold 9,500 United Therapeutics (UTHR) shares after exercising options at $117.76 each.

Stock Titan report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 19h ago

An 8,300-share planned sale follows an option exercise by United Therapeutics (UTHR) counsel.

Stock Titan report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 22h ago

A Houston site is built to make pig kidneys and hearts for United Therapeutics’ organ program.

Stock Titan report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

After exercising options at $117.76, United Therapeutics (UTHR) CEO family trusts sell 9,500 shares.

Stock Titan report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A CEO trust exercises options at $117.76 a share and sells 9,500 United Therapeutics (UTHR) shares.

Stock Titan report covering United Therapeutics Corporation (UTHR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

UTHR Bull vs. Bear Conversation Board — What's Your Call at $598.72?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON UTHR 🐻 33% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $700.38 (+18.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is UTHR (A- • RQD 82/100) a Buy at $593.54?

Welcome to the UTHR (United Therapeutics Corporation) Roar Pit. Current RQD Composite is 82/100 (Roarable Buy — Superior Risk/Reward) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (20.1% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $498.57 (-16.0%)

Spot @ $593.54

Pump the brakes on UTHR — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on UTHR, but look at what you are paying: 19.1x trailing P/E with 87.9% gross margins. Unless United Therapeutics Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $735.99 (+24.0%)

Spot @ $593.54

UTHR cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on UTHR, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $593.54 (52-wk range $430.02 - $609.99), any beat on forward guidance forces shorts and underweight funds to chase.